Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.36 |
| ▸ | PYGM | P11217 | 3/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119152 | 0.85 | GAA (0.38) | SCN9AEPHX2NPY1RPYGLPYGM | |
| SCHEMBL7423564 | 0.84 | KYAT1 (0.46) | PYGLPYGM | |
| SCHEMBL7419284 | 0.84 | AADAT (0.40) | SCN9APYGLPYGM | |
| SCHEMBL3781776 | 0.82 | CCKBR (0.39) | PYGLPYGM | |
| SCHEMBL9974767 | 0.80 | DRD2 (0.37) | SCN9APYGLPYGM | |
| SCHEMBL5132457 | 0.77 | NPY1R (0.52) | SCN9ANPY1RKMT2AL3MBTL1 | |
| SCHEMBL3777420 | 0.77 | CCKBR (0.39) | PYGLPYGM | |
| SCHEMBL14193208 | 0.76 | PYGL (0.43) | PYGLPYGM | |
| SCHEMBL23119153 | 0.76 | NPY1R (0.45) | SCN9ANPY1R | |
| SCHEMBL24190214 | 0.75 | GAA (0.38) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2012082853-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | LIPG 1067/4885SCN9A 596/4885HDAC1 1103/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LIPG 1067/4885SCN9A 596/4885HDAC1 1103/4885 |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LIPG 1067/4885SCN9A 596/4885HDAC1 1103/4885 |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LIPG 1067/4885SCN9A 596/4885HDAC1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.